VeriStrat validated in patients with non-small-cell lung cancer

The Lancet Oncology

Volumn 15, Issue 7, 2014, Pages 671-672

  Butts, Charles A ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

BLOOD ANALYSIS EQUIPMENT; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; EGFR GENE; GENE MUTATION; HUMAN; LUNG NON SMALL CELL CANCER; MASS SPECTROMETRY; NOTE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL RATE; SURVIVAL TIME;

BLOOD PROTEINS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; PROTEIN KINASE INHIBITORS; PROTEOMICS; QUINAZOLINES;

EID: 84901626605     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)70203-7     Document Type: Note

References (10)

1. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
2. Keedy VL, Temin S, Somerfield MR, et al. American Society of Medical Oncology Provisional Opinion: epidermal growth factor receptor mutation testing for patients with advanced non-small cell lung cancer considering first line EGFR tyrosine kinase inhibitor therapy. J Clin Onc 2011, 29:2121-2127.
3. Peters S, Adjei AA, Gridelli C, et al. Metastatic Non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012, 23(suppl 7):vii56-vii64.
4. Taguchi F, Solomon B, Gregorc V, et al. Mass spectrometry to classify non-small cell lung cacneer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. J Natl Cancer Inst 2007, 99:838-846.
5. Gregorc V, Novello S, Lazzari C, et al. Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial. Lancet Oncol 2014, published online May 13. http://dx.doi.org/10.1016/S1470-2045(14)70162-7.
6. Freidlin B, McShane LM, Korn EL Randomized clinical trials with biomarkers: design issues. J Natl Cancer Inst 2010, 102:152-160.
7. Lee J-K, Hahn S, Kim D-W, et al. Epidermal growth factor receptor tyrosine kinase inhibitors versus conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis. JAMA 2014, 311:1430-1437.
8. Okano Y, Ando M, Asami K, et al. Randomized phase III trial of erlotinib (E) versus docetaxel (D) as second- or third-line therapy in patients with advanced non-small cell lung cancer (NSCLC) who have wild type or mutant epidermal growth factor receptor (EGFR): Docetaxel and Erlotinib Lung Cancer Trial (DELTA). J Clin Oncol 2013, 31:8006. (abstr).
9. Yang J, Cheng Y, Zhao M, et al. A phase II trial comparing pemetrexed with gefitinib as second-line treatment in non-squamous non-small cell lung cancer patients with wild-type EGFR (CTONG 0806). Proc Am Soc Clin Oncol 2013, 31:8042. (abstr).
10. Garassino MC, Martelli O, Broggini M, et al. Erlotinib versus doecetaxel as second-line treatment of patients with advanced non-small cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol 2013, 14:981-988. on behalf of the TAILOR trialists.